Wana Schulze and Ivan Yoon will lead CVC investments at Telefónica’s seed and early-stage Brazilian subsidiaries.

The chief executive officer of Debiopharm's corporate subsidiary will be replaced by Marc Cikes in early June

Ensoma's $135m series B was one of five big rounds for early-stage drug developers week despite a pharma sector that is becoming ever more selective.

The hospital group plans to back more than 50 companies through Catalyst, with workplace, big data and customer experience software startups all in the frame.

The pharmaceutical company's Social Impact Venture Capital Portfolio helps improve healthcare access for black and other minority groups in the US.

Technology is starting to make it possible to understand the complex interactions of the microbiome in more detail.

BiomeSense, a University of Chicago spin out, wants to create a 10m record dataset for the microbiome sector.

Sometimes called the “last organ under active research”, the human microbiome and therapeutics relating to it are attracting dollars and interest in the innovation community – albeit still from a low base.

A treatment for all lung diseases, a rose petal-inspired coating to make solar cells more efficient and a device to resuscitate newborns are among this month's picks.

GSK remains an investor in the new $600m Fund II, but with a smaller financial presence as SR One positions itself to connect startups to multiple companies across the pharmaceuticals sector.